Boston Scientific Reports Positive Trial Data for HeartLogic Heart Failure Diagnostic

Boston Scientific (BSX) said on Tuesday that data presented at the Heart Failure Society of America’s 21st annual scientific meeting confirmed the HeartLogic Diagnostic accurately enhanced the ability to classify patients at high or low-risk of experiencing a future HF event.

The HeartLogic Diagnostic provides continuous measurement of a patient’s heart failure by combining data from sensors evaluating heart sounds, respiration rate and volume, thoracic impedance, heart rate and activity.

“The data presented today further prove the value of the HeartLogic Diagnostic in the early prediction of HF events,” Boston Scientific’s chief medical officer Kenneth Stein said in a statement. “Our commitment to innovation in heart failure remains steadfast, and we look forward to the seeing continued results of the alert in a clinical setting.”

The company received CE Mark and U.S. Food and Drug Administration approval of the HeartLogic Diagnostic within the Resonate family of implantable cardioverter defibrillator and CRT-D systems earlier this year. The new line of devices will become commercially available later this year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.